Independent Advisor Alliance Acquires Shares of 2,036 Masimo Co. (NASDAQ:MASI)

Independent Advisor Alliance acquired a new stake in shares of Masimo Co. (NASDAQ:MASI) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 2,036 shares of the medical equipment provider’s stock, valued at approximately $239,000.

Other hedge funds also recently bought and sold shares of the company. Massmutual Trust Co. FSB ADV lifted its position in shares of Masimo by 140.6% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares in the last quarter. Byrne Asset Management LLC acquired a new position in Masimo in the fourth quarter worth approximately $28,000. NBC Securities Inc. acquired a new position in Masimo in the third quarter worth approximately $34,000. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Masimo during the fourth quarter valued at approximately $36,000. Finally, Harvest Fund Management Co. Ltd grew its holdings in Masimo by 2,888.9% during the fourth quarter. Harvest Fund Management Co. Ltd now owns 538 shares of the medical equipment provider’s stock valued at $62,000 after purchasing an additional 520 shares during the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on the company. Piper Sandler increased their price target on Masimo from $117.00 to $126.00 and gave the company a “neutral” rating in a report on Wednesday, May 8th. Wells Fargo & Company upgraded Masimo from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $117.00 to $160.00 in a report on Monday, March 25th. BTIG Research increased their price target on Masimo from $145.00 to $166.00 and gave the company a “buy” rating in a report on Monday, March 25th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Wednesday, May 8th. Finally, Stifel Nicolaus upgraded Masimo from a “hold” rating to a “buy” rating and increased their price target for the company from $148.00 to $170.00 in a report on Monday, April 15th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $138.71.

Insider Buying and Selling at Masimo

In other Masimo news, Director Craig B. Reynolds sold 40,000 shares of Masimo stock in a transaction on Friday, April 26th. The stock was sold at an average price of $136.17, for a total transaction of $5,446,800.00. Following the completion of the transaction, the director now directly owns 7,406 shares of the company’s stock, valued at $1,008,475.02. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 9.70% of the company’s stock.

Masimo Stock Up 1.7 %

Shares of MASI stock opened at $126.60 on Thursday. The stock has a market cap of $6.72 billion, a P/E ratio of 86.12 and a beta of 0.99. Masimo Co. has a one year low of $75.22 and a one year high of $169.58. The stock has a fifty day moving average price of $134.61 and a 200 day moving average price of $122.42. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.31 and a quick ratio of 1.31.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, May 7th. The medical equipment provider reported $0.77 EPS for the quarter, topping the consensus estimate of $0.71 by $0.06. The firm had revenue of $492.80 million during the quarter, compared to analysts’ expectations of $487.70 million. Masimo had a return on equity of 13.26% and a net margin of 4.01%. Masimo’s quarterly revenue was down 12.8% compared to the same quarter last year. During the same period last year, the business earned $0.87 earnings per share. Analysts predict that Masimo Co. will post 3.64 earnings per share for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.